Dianthus Therapeutics, Inc. Board of Directors

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Mr. Marino Garcia M.B.A.

Mr. Marino Garcia M.B.A.

President, CEO & Director

Mr. Edward G. Carr

Mr. Edward G. Carr

Chief Accounting Officer

Mr. Judson Taylor

Mr. Judson Taylor

Head of Technical Operations

Mr. Ryan Savitz

Mr. Ryan Savitz

Chief Financial Officer & Chief Business Officer

Ms. Kristina Maximenko

Ms. Kristina Maximenko

Chief People Officer

Mr. Adam M. Veness Esq.

Mr. Adam M. Veness Esq.

Senior VP, General Counsel & Secretary

Ms. Jennifer Davis Ruff

Ms. Jennifer Davis Ruff

VP and Head of Investor Relations & Corporate Affairs.

Ms. Rashieda Gluck

Ms. Rashieda Gluck

Head of Clinical Development Operations

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.